sacubitril

$435 - $460
Product name: sacubitril
CAS: 1038924-61-6
MF: C17H17NO
MW: 251.32
EINECS:
MDL Number:MFCD26401537
Synonyms:sacubitril;(S)-5-[(biphenyl-4-yl)Methyl]pyrrolidin-2-one;(S)-5-([1,1'-biphenyl]-4-ylMethyl)pyrrolidin-2-one;2-Pyrrolidinone, 5-([1,1'-biphenyl]-4-ylmethyl)-, (5S)-;sacubitril ISO 9001：2015 REACH

Price2 Properties Safety Information Description

2 prices

Selected condition：

Brand

Chemenu
Crysdot

Package

ManufacturerChemenu
Product numberCM198982
Product description(S)-5-([1,1''-biphenyl]-4-ylmethyl)pyrrolidin-2-one 95%
Packaging1g
Price$435
Updated2021-12-16
Buy

ManufacturerCrysdot
Product numberCD11361443
Product description(S)-5-([1,1'-Biphenyl]-4-ylmethyl)pyrrolidin-2-one 95+%
Packaging1g
Price$460
Updated2021-12-16
Buy

Manufacturer	Product number	Product description	Packaging	Price	Updated	Buy
Chemenu	CM198982	(S)-5-([1,1''-biphenyl]-4-ylmethyl)pyrrolidin-2-one 95%	1g	$435	2021-12-16	Buy
Crysdot	CD11361443	(S)-5-([1,1'-Biphenyl]-4-ylmethyl)pyrrolidin-2-one 95+%	1g	$460	2021-12-16	Buy

Properties

Boiling point :473.6±24.0 °C(Predicted)
Density :1.117±0.06 g/cm3(Predicted)
pka :16.31±0.40(Predicted)

Safety Information

Symbol(GHS):

Signal word:

Hazard statements:

Code	Hazard statements	Hazard class	Category	Signal word	Pictogram	P-Codes

Precautionary statements:

Description

Sacubitril is a neprilysin inhibitor prodrug developed by Novartis that was approved as part of an orally administered supramolecular sodium salt complex with the angiotensin receptor blocker (ARB) valsartan in the U.S. and EU in 2015. Sacubitril/valsartan (also known as LCZ-696) is a first-in-class dual angiotensin receptor blocker neprilysin inhibitor (ARNI) marketed for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). It represents a novel mechanistic approach to targeting HFrEF and is the first pharmacologic agent approved for HFrEF since 2004. Sacubitril is metabolized by enzymatic conversion of the ethyl ester to the active diacid (LBQ-657, structure not disclosed), which inhibits neprilysin and prevents endogenous natriuretic peptide degradation. Neprilysin inhibitors like sacubitril are not effective as monotherapy and need to be combined with a reninangiotensin aldosterone system (RAAS) inhibitor such as valsartan. Notably, dual neprilysin and angiotensin-converting enzyme (ACE) inhibition, as in omapatrilat, was found to be associated with an increased risk of life-threatening angioedema due to increased bradykinin levels. In phase III clinical trials, sacubitril/ valsartan displayed a superior safety profile to enalapril, with a 20% decrease in heart failure hospitalizations or cardiovascular death and a 16% reduction in the risk of death from any cause. Sacubitril/valsartan is now recommended as the standard of care for HFrEF as an alternative to ACEs and ARBs.

More related product prices

LCZ696 InteMediate LCZ696 2-Pyrrolidinone, 5-([1,1'-biphenyl]-4-ylMethyl)-3-Methyl-, (3R,5S)- (R,E)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoic acid AHU-377 Valsartan ahu377 isomer 2